Moderna (MRNA) stock advanced after FDA authorized mFLUSIVA, its first mRNA flu vaccine for adults 50+, launching in the 2026-2027 respiratory season. The post Moderna (MRNA) Stock Climbs After FDA Greenlights First mRNA Flu Vaccine mFLUSIVA appeared first on Blockonomi.